GlassScriptPhysician profile
William G Plunkett
NPI 1871553016
$3,474.10
in general payments reported to CMS, 2019-2025
46 companies · $688 in 2025
The $688 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,383 · 2020: $399 · 2021: $125 · 2023: $448 · 2024: $430 · 2025: $688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,567.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $319.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $296.99 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $291.24 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $253.22 | 2019-2023 | Verquvo, Steglatro, Steglujan |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $240.44 | 2019-2025 | Xifaxan |
| Abbvie INC. | $231.23 | 2023-2025 | |
| Lilly USA, LLC | $155.47 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.37 | 2019-2025 | |
| Abbott Laboratories | $153.94 | 2023-2025 | Freestyle Libre 3, Freestyle Libre |
| Astrazeneca Pharmaceuticals LP | $152.13 | 2019-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $143.94 | 2023-2025 | |
| Amarin Pharma, INC. | $112.53 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $87.85 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.52 | 2019-2020 | |
| Amgen INC. | $82.65 | 2019-2025 | Evenity |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $44.86 | 2025 | Tymlos |
| Smith+Nephew, INC. | $44.50 | 2019-2020 | |
| Corium, LLC | $41.90 | 2023-2024 | Azstarys |
| Jazz Pharmaceuticals INC. | $39.49 | 2020 | |
| Shire North American Group INC | $35.69 | 2019 | |
| Esperion Therapeutics, INC. | $32.24 | 2023 | Nexletol |
| Astellas Pharma US INC | $31.42 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $30.63 | 2023-2024 | Gemtesa |
| Daiichi Sankyo INC. | $28.94 | 2019 | |
| Dexcom, INC. | $25.94 | 2024 | Dexcom G6 Transmitter |
| Vanda Pharmaceuticals INC. | $25.90 | 2019 | |
| Allergan, INC. | $23.96 | 2020 | |
| Alexion Pharmaceuticals, INC. | $22.48 | 2024 | Strensiq |
| E.R. Squibb & Sons, L.L.C. | $21.26 | 2025 | Camzyos |
| Sequel Med Tech, LLC | $20.99 | 2025 | Twiist |
| Ibsa Pharma INC. | $20.05 | 2025 | Tirosint, Licart, Flector |
| Ge Healthcare | $19.91 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $19.79 | 2024 | Crysvita |
| Seqirus USA INC | $18.13 | 2025 | Fluad, Flucelvax |
| Harmony Biosciences LLC | $17.65 | 2025 | |
| Supernus Pharmaceuticals, INC. | $17.28 | 2019 | |
| Amneal Pharmaceuticals LLC | $16.99 | 2025 | Unithroid |
| Genentech USA, INC. | $15.10 | 2019 | |
| Adlon Therapeutics L.P. | $14.77 | 2019 | |
| Lundbeck LLC | $14.21 | 2023 | Rexulti |
| Gilead Sciences, INC. | $13.59 | 2020 | |
| Boston Scientific Corporation | $13.53 | 2023 | Watchman Flx |
| Avanir Pharmaceuticals, INC. | $11.23 | 2019 | |
| Phathom Pharmaceuticals, INC. | $11.05 | 2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $11.00 | 2019 | |
| Beta Bionics, INC. | $8.41 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Plunkett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.